We are live on ! Find out more

POM

Pomdoctor Ltd

POM

Market cap $7.4M

0.7980 USD

-0.0310

3.74%

At close Updated Sep 18, 4:00 PM EDT

1 day

-3.74%

5 days

6.41%

1 month

-15.47%

3 months

-38.14%

6 months

-88.66%

Year to date

-86.41%

1 year

-98.9%

5 years

-98.9%

10 years

-98.9%

About: Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.

Employees: 165

Healthcare Pharmaceutical Retailers

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept.

POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy

GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced the formal initiation of its U.S. market entry preparations, marking a decisive advancement in its global growth strategy. As part of the initiative, Pomdoctor has recently commenced recruitment for core U.S.-based leadership and operational roles, completed an initial assessment of the U.S. healthcare market, and begun structuring a dedicated local compliance and regulatory framework.

POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The Company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement.

POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine

POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure

Anchoring Established Healthcare Operations to Technology-Enabled Growth Opportunities GUANGZHOU, China, Aug. 3, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its four-tier diversified revenue structure, which is designed to build on the Company's established healthcare operations while developing scalable, technology-enabled services. The Company's four-tier revenue structure consists of B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, along with pharmaceutical real-world study ("RWS") and real-world data ("RWD") services.

POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure

POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities

GUANGZHOU, China, July 15, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its ongoing efforts to strengthen its healthcare data ecosystem, by leveraging real-world data ("RWD"), artificial intelligence ("AI"), wearable technologies, remote patient monitoring ("RPM") capabilities and physician resources to enable more personalized, predictive and continuous healthcare management. As digital transformation accelerates across healthcare systems worldwide, RWD is emerging as a critical foundation for AI-enabled healthcare innovation.

POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities

POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

GUANGZHOU, China, July 13, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on July 10, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). As a result, the matter has been closed.

POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare

GUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its continued efforts in building an AI-powered chronic disease management ecosystem. The Company is integrating artificial intelligence ("AI"), remote patient monitoring ("RPM"), wearable technologies and real-world healthcare data to evolve toward a predictive, continuous and personalized healthcare service provider.

POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare

POMDOCTOR LIMITED Announces Strategic Upgrade Toward Infrastructure for Predictive Healthcare Data and Services

GUANGZHOU, China, July 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic upgrade, officially positioning the Company as a foundational infrastructure provider for predictive healthcare data and services. The strategic upgrade reflects the Company's continued evolution from a traditional online healthcare platform toward an artificial intelligence ("AI")-enabled healthcare infrastructure provider.

POMDOCTOR LIMITED Announces Strategic Upgrade Toward Infrastructure for Predictive Healthcare Data and Services

POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026

GUANGZHOU, China, June 17, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that, as previously announced on May 28, 2026, the ratio change of its American depositary shares (the "ADSs") to Class A ordinary shares from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares (the "ADS Ratio Change") will become effective on June 22, 2026, U.S. Eastern Time (the "Effective Date"). For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split.

POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026

POMDOCTOR LIMITED Announces Plan to Implement ADS Ratio Change

GUANGZHOU, China, May 28, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its Class A ordinary shares (the "ADS Ratio Change"), from the current ratio of one (1) ADS representing one-sixth (1/6) Class A ordinary share to a new ratio of one (1) ADS representing three (3) Class A ordinary shares. For the Company's ADS holders, the ADS Ratio Change will have the same effect as a one-for-eighteen reverse ADS split.

POMDOCTOR LIMITED Announces Plan to Implement ADS Ratio Change

See News Rankings

Price charts implemented using Lightweight Charts™